Allergies, Bacterium, Containment and Immune Response

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Allergies

Bacterium

Containment

Immune Response

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Therapyx will develop and manufacture the IL-12-containing microspheres in the vaccine called GneX12.

Vaccination

Vaccination Vaccine Development Bacterium

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

NOVEMBER 6, 2020

Related: Red Meat Allergy Test Gets FDA Clearance. “We Symvivo’s bacTRL Gene Therapy Platform is designed and optimized to address limitations associated with typical vaccines, including the inability to accommodate large or multiple genes, lack of specificity to targeted tissue and poor control over immune response, says the company.

Clinical Trials

Clinical Trials Clinical Trials Vaccination Vaccine

Clinical Research Informer

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

Stay Connected